VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

Posted: June 14, 2024 at 2:45 am

VYN202 has been designed to achieve class-leading potency and BD2-selectivity

See more here:
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

Related Posts